Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-02-2012 | Editorial

Amyloid-β imaging with PET in Alzheimer’s disease: is it feasible with current radiotracers and technologies?

Authors: Mateen C. Moghbel, Babak Saboury, Sandip Basu, Scott D. Metzler, Drew A. Torigian, Bengt Långström, Abass Alavi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2012

Excerpt

Although it afflicts an estimated 26.6 million people worldwide—a figure that is expected to quadruple by 2050—Alzheimer’s disease (AD) has yet to be fully understood etiologically, diagnostically, or therapeutically [1]. For decades, the most widely accepted definite diagnosis of AD has been the histological observation of senile plaques composed of amyloid-β (Aβ) and neurofibrillary tangles comprising tau [2‐4]. Theories abound as to the mechanisms behind these deposits of Aβ and tau, one of the most prominent of which is the “amyloid hypothesis.” This hypothesis proposes that the cleavage of amyloid precursor protein by β-secretase and γ-secretase causes Aβ42 to accumulate as senile plaques, which results in synaptic and neuronal injury [5]. …

Available only for authorised users

Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–91.PubMedCrossRef

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34(7):939–44.PubMed

Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734–46.PubMedCrossRef

Khachaturian ZS. Diagnosis of Alzheimer’s disease. Arch Neurol. 1985;42(11):1097–105.PubMedCrossRef

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.PubMedCrossRef

Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (Florbetapir F18). J Nucl Med. 2010;51(6):913–20.PubMedCrossRef

Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA. 2011;305(3):275–83.PubMedCrossRef

Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011. http://archneur.ama-assn.org/cgi/content/full/archneurol.2011.150v1. Accessed 4 October 2011.

Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicenter phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424–35.PubMedCrossRef

10.

Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210–7.PubMedCrossRef

11.

Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68(3):319–29.PubMedCrossRef

12.

Barthel H, Luthardt J, Becker G, Patt M, Hammerstein E, Hartwig K, et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls. Eur J Nucl Med Mol Imaging. 2011;38(9):1702–14.PubMedCrossRef

13.

Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology. 2007;68(19):1603–6.PubMedCrossRef

14.

Kemppainen NM, Aalto S, Wilson IA, Nagren K, Helin S, Bruck A, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology. 2006;67(9):1575–80.PubMedCrossRef

15.

Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex. 1991;1(1):103–16.PubMedCrossRef

16.

Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351–7.PubMedCrossRef

17.

Brun A, Gustafson L. Distribution of cerebral degeneration of Alzheimer’s disease. Arch Psychiatr Nervenkr. 1976;223(1):15–33.PubMedCrossRef

18.

Shin J, Kepe V, Small GW, Phelps ME, Barrio JR. Multimodal imaging of Alzheimer pathophysiology in the brain’s default mode network. Int J Alzheimers Dis. 2011:687945.PubMed

19.

Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A. 2002;99(7):4703–7.PubMedCrossRef

20.

Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, et al. Dynamics of gray matter loss in Alzheimer’s disease. J Neurosci. 2003;23(3):994–1005.PubMed

21.

Yetkin FZ, Rosenberg RN, Weiner MF, Purdy PD, Cullum CM. FMRI of working memory in patients with mild cognitive impairment and probable Alzheimer’s disease. Eur Radiol. 2006;16(1):193–206.PubMedCrossRef

22.

Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med. 2008;49(3):390–8.PubMedCrossRef

23.

Herholz K, Salmon E, Perani DBaron JC, Holthoff V, Frolich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17(1):302–16.PubMedCrossRef

24.

Furst AJ, Lal RA. Amyloid-B and Glucose Metabolism in Alzheimer’s Disease. J Alzheimers Dis. 2011;26:105–16.PubMed

25.

Attems J, Quass M, Jellinger KA, Lintner F. Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J Neurol Sci. 2007;257(1–2):49–55.PubMedCrossRef

26.

Xu D, Yang C, Wang L. Cerebral amyloid angiopathy in aged Chinese: a clinic-neuropathological study. Acta Neuropathol. 2003;106(1):89–91.PubMed

27.

Ti M. The incidence of cerebral amyloid angiopathy in Alzheimer’s disease. Neurology. 1975;25(2):120–6.

28.

Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease. Neurology. 1996;46(6):1592–6.PubMed

29.

Esiri MM, Wilcock GK. Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry. 1986;49(11):1221–6.PubMedCrossRef

30.

Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li QX, Masters CL, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50(2):198–204.PubMedCrossRef

31.

Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306–19.PubMedCrossRef

32.

Blomquist G, Engler H, Nordberg A, Ringheim A, Wall A, Forsberg A, et al. Unidirectional influx and net accumulation of PIB. Open Neuroimaging J. 2008;2:114–25.CrossRef

33.

Thomas BA, Erlandsson K, Modat M, Thurfjell L, Vandenberghe R, Ourselin S, et al. The importance of appropriate partial volume correction for PET quantification in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2011;38(6):1104–19.PubMedCrossRef

34.

Hickeson M, Yun M, Matthies A, Zhuang H, Adam LE, Lacorte L, et al. Use of corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging. 2002;29(12):1639–47.PubMedCrossRef

35.

Kessler RM, Ellis JR, Eden M. Analysis of emission tomographic scan data: limitations imposed by resolution and background. J Comput Assist Tomogr. 1984;8(3):514–22.PubMedCrossRef

36.

Connor DM, Benveniste H, Dilmanian FA, Kritzer MF, Miller LM, Zhong Z. Computed tomography of amyloid plaques in a mouse model of Alzheimer’s disease using diffraction enhanced imaging. Neuroimage. 2009;46(4):908–14.PubMedCrossRef

37.

Sanchez-Crespo A, Andreo P, Larsson SA. Positron flight in human tissues and its influence on PET image spatial resolution. Eur J Nucl Med Mol Imaging. 2004;31(1):44–51.PubMedCrossRef

38.

Bussiere T, Friend PD, Sadeghi N, Wicinski B, Lin GI, Bouras C, et al. Stereologic assessment of the total cortical volume occupied by amyloid deposits and its relationship with cognitive status in aging and Alzheimer’s disease. Neuroscience. 2002;112(1):75–91.PubMedCrossRef

39.

Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in patient with Alzheimer disease: a case report. Arch Neurol. 2009;66(12):1557–62.PubMedCrossRef

40.

Lin KJ, Hsu WC, Hsiao IT, Wey SP, Jin LW, Skovronsky D, et al. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent – a pilot study. Nucl Med Biol. 2010;37(4):497–508.PubMedCrossRef

41.

Bergström M, Grahnén A, Långström B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol. 2003;59(5-6):357–66.PubMedCrossRef

42.

Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, et al. Florbetapir F-18: a histopathologically validated beta-amyloid positron emission tomography imaging agent. Semin Nucl Med. 2011;41(4):300–4.PubMedCrossRef

43.

Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS. Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer’s disease. Neurobiol Aging. 1993;14(6):589–96.PubMedCrossRef

44.

Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, et al. Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011;7(1):102–11.CrossRef

45.

Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized control trial. JAMA. 2009;302(23):2557–64.PubMedCrossRef

46.

Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73(24):2061–70.PubMedCrossRef

47.

Panza F, Frisardi V, Imbimbo BP, D’Onofrio G, Pietrarossa G, Seripa D, et al. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. Immunotherapy. 2010;2(6):767–82.PubMedCrossRef

48.

Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D’Onofrio G, Logroscino G, et al. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?. Expert Opin Investig Drugs. 2011;20(3):325–41.PubMedCrossRef

49.

Robinson SR, Bishop GM, Lee HG, Munch G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging. 2004;25(5):609–15.PubMedCrossRef

50.

Munch G, Robinson SR. Alzheimer’s vaccine: a cure as dangerous as the disease? J Neural Transm. 2002;109(4):537–9.PubMedCrossRef

51.

Rafii MS, Aisen PS. Recent developments in Alzheimer’s disease therapeutics. BMC Med. 2009;7:7.PubMedCrossRef

52.

Sabbagh MN. Drug development for Alzheimer’s disease: where are we now and where are we headed?. Am J Geriatr Pharmacother. 2009;7(3):167–85.PubMedCrossRef

53.

Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med. 1998;338(8):506–11.PubMedCrossRef

54.

Ranginwala NA, Hynan LS, Weiner MF, White III CL. Clinical criteria for the diagnosis of Alzheimer disease: still good after all these years. Am J Geriatr Psychiatry. 2008;18(5):384–8.CrossRef

55.

Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509–17.PubMedCrossRef

Title: Amyloid-β imaging with PET in Alzheimer’s disease: is it feasible with current radiotracers and technologies?
Authors: Mateen C. Moghbel
Babak Saboury
Sandip Basu
Scott D. Metzler
Drew A. Torigian
Bengt Långström
Abass Alavi
Publication date: 01-02-2012
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-011-1960-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Amyloid-β imaging with PET in Alzheimer’s disease: is it feasible with current radiotracers and technologies?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2012

Frederik Barkhof, Nick C. Fox, Antonio J. Bastos-Leite, Philip Scheltens (eds): Neuroimaging in Dementia

Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy

Multiphase contrast-enhanced CT with highly concentrated contrast agent can be used for PET attenuation correction in integrated PET/CT imaging

Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset

Changes observed in radionuclide bone scans during and after teriparatide treatment for osteoporosis

Laparoscopic sentinel lymph node (SLN) versus extensive pelvic dissection for clinically localized prostate carcinoma